Study comparing MAGiC to conventional MR imaging published in American Journal of Neuroradiology (AJNR).
The study – now published in AJNR – was conducted by GE Healthcare as a blinded, multi-center, multi-reader clinical study comparing MAGiC to conventional MR imaging. MAGiC is a customized version of SyntheticMR’s SyMRI® IMAGE software marketed by GE Healthcare under a license agreement. Clinicians from six different sites compared the two methods and verified that the image quality of MAGiC was comparable to conventional images.
”The study proves the potential of SyMRI® IMAGE to become a standard method for conducting
neuro scans in a fraction of time and in helping clinicians diagnosing patients”, says Stefan Tell, CEO of SyntheticMR.
The study comprising a set of 1526 images were read by 7 neuroradiologists comparing synthetic and conventional MR brain images from 109 subjects with neuroimaging indications. The results revealed that the diagnostic quality of the images generated synthetically were non-inferior to conventional imaging.
MAGiC (Magnetic Resonance Image Compilation) is the industry’s first multi-contrast magnetic resonance (MR) technique cleared with the U.S. FDA. The technique gives clinicians more data than conventional scanning in a substantially shorter time frame*. MAGiC gives users the flexibility to adjust the images retrospectively leading to significant timesaving, fewer rescans and therefore cost savings, which combined, can assist the clinician in making a more decisive diagnosis.
For additional information, please contact Stefan Tell, CEO, +46 73 373 40 90 or Jonas Hurtig, Head of Marketing and Commercial Affairs, +46 76 311 61 14.
* Based on MAGiC clinical study of 109 patients from 6 separate institutions.
The full study can be acquired on http://www.ajnr.org/content/early/2017/04/27/ajnr.A5227
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple, adjustable contrast images and quantitative data from a single 5-6 minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is a CE-marked product and is FDA 510(k) pending. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com